IGC Pharma (IGC) Income towards Parent Company (2010 - 2025)
IGC Pharma (IGC) reported Income towards Parent Company of -$1.8 million for Q3 2025, down 6.06% year-over-year from -$1.9 million in Q3 2024, and down 13.88% quarter-over-quarter from -$1.6 million in Q2 2025.
IGC Pharma (IGC) Income towards Parent Company (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has 16 years of Income towards Parent Company data on file, last reported at -$1.8 million in Q3 2025.
- Income towards Parent Company for Q3 2025 came in at -$1.8 million, down 6.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.4 million (up 51.98% YoY), and the FY2026 annual result was -$2.4 million, up 66.27% from the prior year.
- Income towards Parent Company slipped to -$1.8 million in Q3 2025 per IGC's latest filing, from -$1.6 million in the prior quarter.
- Over five years, Income towards Parent Company peaked at -$1.2 million in Q1 2025 and troughed at -$6.5 million in Q1 2022.
- A 5-year average of -$2.8 million and a median of -$2.4 million in 2021 frame the typical range for Income towards Parent Company.
- The sharpest annual moves came in 2021 and 2024: Income towards Parent Company plunged 162.16% in 2021, then jumped 67.28% in 2024.
- A 5-year view of Income towards Parent Company shows it stood at -$2.4 million in 2021, then rose by 5.54% to -$2.2 million in 2022, then sank by 148.51% to -$5.6 million in 2023, then jumped by 67.28% to -$1.8 million in 2024, then advanced by 0.44% to -$1.8 million in 2025.
- Business Quant data shows IGC's Income towards Parent Company at -$1.8 million in Q3 2025, -$1.6 million in Q2 2025, and -$1.2 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -1.82 Mn |
| Jun 30, 2025 | -1.60 Mn |
| Mar 31, 2025 | -1.20 Mn |
| Dec 31, 2024 | -1.83 Mn |
| Sep 30, 2024 | -1.72 Mn |
| Jun 30, 2024 | -2.38 Mn |
| Mar 31, 2024 | -2.89 Mn |
| Dec 31, 2023 | -5.59 Mn |
| Sep 30, 2023 | -2.45 Mn |
| Jun 30, 2023 | -2.08 Mn |
| Mar 31, 2023 | -4.03 Mn |
| Dec 31, 2022 | -2.25 Mn |
| Sep 30, 2022 | -2.44 Mn |
| Jun 30, 2022 | -2.79 Mn |
| Mar 31, 2022 | -6.50 Mn |
| Dec 31, 2021 | -2.38 Mn |
| Sep 30, 2021 | -4.34 Mn |
| Jun 30, 2021 | -1.79 Mn |
| Mar 31, 2021 | -2.95 Mn |
| Dec 31, 2020 | -2.32 Mn |